Oxford Biomedica plc (LON:OXB - Get Free Report) shares were up 0.1% during trading on Wednesday . The company traded as high as GBX 433.44 ($5.49) and last traded at GBX 430 ($5.45). Approximately 92,890 shares traded hands during mid-day trading, a decline of 54% from the average daily volume of 201,557 shares. The stock had previously closed at GBX 429.50 ($5.44).
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft increased their price objective on Oxford Biomedica from GBX 250 ($3.17) to GBX 380 ($4.82) and gave the stock a "hold" rating in a research report on Tuesday, September 24th.
Get Our Latest Stock Analysis on Oxford Biomedica
Oxford Biomedica Price Performance
The stock has a market cap of £453.05 million, a PE ratio of -298.61 and a beta of 1.09. The business has a 50 day moving average of GBX 411.09 and a 200-day moving average of GBX 364.39. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 154.88.
About Oxford Biomedica
(
Get Free Report)
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
Further Reading
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
